- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01663870
Technology and Navigation to Improve Survivorship Care
Integrating Technology and Navigation to Improve Survivorship Care in Underserved Populations
The goal of this research study to learn about breast cancer survivorship and possible ways to improve breast cancer survivorship programs using technology.
Objectives:
Objective 1: Assess breast cancer survivors on the acceptability of and preferences for the integration of patient navigation and an eHealth technology platform to improve care in the Survivorship Clinic at Lyndon B. Johnson Hospital.
Objective 2: Assess clinic stakeholders acceptability of and preferences for the integration of patient navigation and an eHealth technology platform to improve care for breast cancer patients in the Survivorship Clinic at Lyndon B. Johnson Hospital.
Study Overview
Status
Conditions
Detailed Description
Breast Cancer Survivors:
If patient agrees to take part in this study, they will visit the cancer survivorship clinic where the following tests and procedures will be performed:
- Patient will have a 30-60 minute interview where they will be asked about cancer-related informational needs, feelings about survivorship care plans, and preferred methods of communication with survivorship clinic staff.
- Patient will be asked about whether they would use the internet and other technologies (such as text messages for appointment reminders) as tools in breast cancer survivorship.
- Patient will use a web-based tool called HealthATM. HealthATM is a website that is designed to provide information and tools to help patients better manage their health. After 10-15 minute session with the website, patient will be asked about how easy the website was to use and other questions about their session.
- Patient will complete a short questionnaire at the end of the interview asking about personal characteristics, how involved they are in their health care, and their attitudes towards the HealthATM website. It should take about 5 minutes to complete this questionnaire.
All interviews will be audiorecorded. All audio recordings will be kept for 5 years and then destroyed. All interview data will be stored in password-protected computers and/or locked file cabinets. There will be no personal identifying information connected to patient's interview answers.
Length of Study:
All of the study procedures will take place at one visit. The visit should last about 60 minutes.
This is an investigational study.
Up to 40 participants will be enrolled in this study. All will be enrolled at LBJ General Hospital.
Clinic Stakeholders:
If clinic staff agree to take part in this study, the following tests and procedures will be performed:
- Clinic staff will take part in a 60-90 minute focus group session where they will be asked about their feelings about survivorship care plans and if they think web-based eHealth programs would be helpful as tools in breast cancer survivorship.
- Clinic staff will be asked about any challenges and barriers they feel are facing the survivorship programs at LBJ.
- Clinic staff will use a web-based tool called HealthATM. HealthATM is a website that provides information and tools to help patients better manage their health. After a 10-15 minute session with the website, they will be asked about how easy the website was to use and other questions about their session.
All focus group sessions will be audiorecorded. All audio recordings will be kept for 5 years and then destroyed. All focus group data will be stored in password-protected computers and/or locked file cabinets. There will be no personal identifying information connected to your focus group answers.
Length of Study:
All of the study procedures will take place at one visit. The visit should last about 60 minutes.
This is an investigational study.
Up to 40 stakeholders will be enrolled in this study. All will be enrolled at LBJ General Hospital.
Study Type
Enrollment (Anticipated)
Contacts and Locations
Study Locations
-
-
Texas
-
Houston, Texas, United States, 77026
- Lyndon B. Johnson Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Age 18-years or older (survivors and stakeholders)
- Ability to read and speak English or Spanish (survivors)
- Ability to read and speak English (stakeholders)
- Active patient at the LBJ General Hospital Survivorship Clinic (survivors only)
- Previous cancer diagnosis with no evidence of recurrence at 3 years or greater following initial diagnosis (survivors only)
- Harris County Hospital District employee offering clinical or administrative support to the LBJGH Cancer Survivorship Clinic (stakeholders only)
- Cancer survivors who are at least 6 months from diagnosis
Exclusion Criteria:
1) None
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
|---|---|
|
Breast Cancer Survivors
Patients in the LBJ General Hospital Cancer Survivorship Clinic.
|
Audio recorded interview at beginning of visit and after using HealthATM website.
10-15 minute session with the HealthATM website.
Questionnaire completion at end of audio recorded interview taking about 5 minutes.
Other Names:
|
|
Clinic Stakeholders
Survivorship clinic stakeholders include clinic nurses, physicians, case managers, oncology patient navigators currently working with those in active treatment, information technology support professionals from the Harris County Hospital District (HCHD).
|
Audio recorded interview at beginning of visit and after using HealthATM website.
10-15 minute session with the HealthATM website.
Focus group session taking 60-90 minutes.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Interview Study of Breast Cancer Survivorship Programs Using Technology
Time Frame: 1 day
|
Breast cancer survivors and clinic staff surveys analyzed regarding acceptability of, and preferences for integration of patient navigation and an eHealth technology platform.
Focus group and interview transcripts analyzed using ATLAS.ti
qualitative analysis software.
To analyze these data, constant comparative method used to conduct thematic analysis of transcribed data.
As secondary check of breast cancer survivor data, calculation of descriptive statistics for measures administered to survivors following interview (frequencies, means, and standard deviations) including Patient Activation Measure and Systems Usability Scale.
|
1 day
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Susan Peterson, MPH, PhD, M.D. Anderson Cancer Center
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2012-0450
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Breast Cancer
-
Northwestern UniversityEisai Inc.UnknownMale Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative...United States
-
University of Southern CaliforniaNational Cancer Institute (NCI)WithdrawnStage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast Cancer
-
Oncoliq US IncRecruitingBreast Cancer Female | Breast Cancer Detection | Breast Cancer Early Stage Breast Cancer (Stage 1-3) | Breast Cancer With Low to Intermediate HER2 Expression | Breast Cancer - Female | Breast Cancer (Early Breast Cancer) | Breast Cancer - Ductal Carcinoma in Situ (DCIS) | Breast Cancer - Infiltrating...Argentina
-
University of California, IrvineNational Cancer Institute (NCI); National Institutes of Health (NIH)CompletedBreast Cancer | HER2-positive Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast Cancer | HER2-negative Breast CancerUnited States
-
University of WashingtonNational Cancer Institute (NCI)CompletedHER2-positive Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-positive Breast CancerUnited States
-
Joseph Baar, MD, PhDCompletedBreast Cancer | Stage I Breast Cancer | Inflammatory Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IIIC Breast CancerUnited States
-
Case Comprehensive Cancer CenterNational Institute on Minority Health and Health Disparities (NIMHD)CompletedCancer Survivor | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage IIIC Breast CancerUnited States
-
University of WashingtonNational Cancer Institute (NCI)CompletedInflammatory Breast Cancer | Male Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IIIC Breast CancerUnited States
-
University of Maryland, BaltimoreSyndax PharmaceuticalsTerminatedStage I Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Triple-negative Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative Breast CancerUnited States
-
National Cancer Institute (NCI)CompletedMale Breast Cancer | Stage IV Breast Cancer | Stage IIIB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast CancerUnited States
Clinical Trials on Audio Recorded Interviews
-
Memorial Sloan Kettering Cancer CenterNational Cancer Institute (NCI); National Institutes of Health (NIH)Completed
-
Karolinska University HospitalCompleted
-
Sengkang General HospitalRecruitingDelirium and Post-operative Cognitive Dysfunction (POCD) | Delirium, Postoperative | Delirium - PostoperativeSingapore
-
University of UtahRecruitingBreast Cancer | Gynecologic CancerUnited States
-
University of UtahRecruiting
-
Duke UniversityNational Cancer Institute (NCI)TerminatedNewly Diagnosed Cancer Patients Who Are HIV Positive and Their Treating OncologistUnited States
-
Hospices Civils de LyonRecruiting
-
Assistance Publique Hopitaux De MarseilleCompleted
-
University of UtahWithdrawnPain | Osteoarthritis, Knee | Osteoarthritis, Hip
-
University of WashingtonNational Institute of Nursing Research (NINR)CompletedChronic PainUnited States